These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 16671943)

  • 1. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
    Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses.
    Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR
    Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
    Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
    Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy.
    Heckelsmiller K; Beck S; Rall K; Sipos B; Schlamp A; Tuma E; Rothenfusser S; Endres S; Hartmann G
    Eur J Immunol; 2002 Nov; 32(11):3235-45. PubMed ID: 12555669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
    Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
    J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
    Hiraide A; Hiroishi K; Ishii S; Eguchi J; Imawari M
    Anticancer Res; 2006; 26(1A):211-8. PubMed ID: 16475701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
    You J; Wang CL; Hao XS
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
    Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
    Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fusion induced reversal of dendritic cell maturation: an altered expression of inflammatory chemokine and chemokine receptors in dendritomas.
    Branham-O'Connor M; Li J; Kotturi HS; Yu X; Wagner TE; Wei Y
    Oncol Rep; 2010 Feb; 23(2):545-50. PubMed ID: 20043120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
    Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
    J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency.
    Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW
    J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor efficacy of fusion cells from esophageal carcinoma cells and dendritic cells as a vaccine in vitro].
    Deng YJ; Xia JC; Zhou J; Wang QJ; Zhang PY; Zhang LJ; Rong TH
    Ai Zheng; 2007 Feb; 26(2):137-41. PubMed ID: 17298741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on the enhancement of DC vaccine to mouse Lewis lung cancer by CpG oligonucleotides].
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ
    Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):1-5. PubMed ID: 15771786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs.
    Novaković S; Stegel V; Kopitar A; Ihan A; Novaković BJ
    Vaccine; 2007 Nov; 25(49):8241-56. PubMed ID: 17980936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice.
    Hu Z; Liu S; Mai X; Hu Z; Liu C
    Cell Immunol; 2010; 262(2):112-9. PubMed ID: 20167310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
    Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
    Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection.
    Celluzzi CM; Falo LD
    J Immunol; 1998 Apr; 160(7):3081-5. PubMed ID: 9531260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells from bench to bedside and back.
    Adema GJ
    Immunol Lett; 2009 Feb; 122(2):128-30. PubMed ID: 19121337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.